Berkan Ocal, Bagcivan Ihsan, Kaya Tijen, Yildirim Kemal, Yildirim Sahin, Doğan Kasim
Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey.
Can J Physiol Pharmacol. 2007 May;85(5):521-6. doi: 10.1139/y07-033.
The radial artery (RA) is used as a spastic coronary bypass graft. This study was designed to investigate the mechanism of vasorelaxant effects of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA/NO (diethylamine/nitric oxide), a NO-nucleophile adduct, on the human RA. RA segments (n = 25) were obtained from coronary artery bypass grafting patients and were divided into 3-4 mm vascular rings. Using the isolated tissue bath technique, the endothelium-independent vasodilatation function was tested in vitro by the addition of cumulative concentrations of YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) following vasocontraction by phenylephrine in the presence or absence of 10-5 mol/L ODQ (1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one), the selective sGC inhibitor, 10-7 mol/L iberiotoxin, a blocker of Ca2+-activated K+ channels, or 10-5 mol/L ODQ plus 10-7 mol/L iberiotoxin. We also evaluated the effect of YC-1 and DEA/NO on the cGMP levels in vascular rings obtained from human radial artery (n = 6 for each drug). YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) caused the concentration-dependent vasorelaxation in RA rings precontracted with phenylephrine (10-5 mol/L) (n = 20 for each drug). Pre-incubation of RA rings with ODQ, iberiotoxin, or ODQ plus iberiotoxin significantly inhibited the vasorelaxant effect of YC-1, but the inhibitor effect of ODQ plus iberiotoxin was significantly more than that of ODQ and iberiotoxin alone (p < 0.05). The vasorelaxant effect of DEA/NO almost completely abolished in the presence of ODQ and iberiotoxin plus ODQ, but did not significantly change in the presence of iberiotoxin alone (p > 0.05). The pEC50 value of DEA/NO was significantly lower than those for YC-1 (p < 0.01), with no change Emax values in RA rings. In addition, YC-1-stimulated RA rings showed more elevation in cGMP than that of DEA/NO (p < 0.05). These findings indicate that YC-1 is a more potent relaxant than DEA/NO in the human RA. The relaxant effects of YC-1 could be due to the stimulation of the sGC and Ca2+-sensitive K+channels, whereas the relaxant effects of DEA/NO could be completely due to the stimulation of the sGC. YC-1 and DEA/NO may be effective as vasodilator for the short-term treatment of perioperative spasm of coronary bypass grafts.
桡动脉(RA)被用作痉挛性冠状动脉旁路移植血管。本研究旨在探讨一氧化氮(NO)非依赖性可溶性鸟苷酸环化酶(sGC)激活剂YC-1(3-(5'-羟甲基-2'-呋喃基)-1-苄基吲唑)和NO亲核加合物DEA/NO(二乙胺/一氧化氮)对人桡动脉血管舒张作用的机制。从冠状动脉旁路移植手术患者获取RA节段(n = 25),并将其分成3 - 4毫米的血管环。采用离体组织浴技术,在存在或不存在10 - 5摩尔/升ODQ(1H-(1,2,4)恶二唑(4,3 - a)喹喔啉 - 1 - 酮)(一种选择性sGC抑制剂)、10 - 7摩尔/升iberiotoxin(一种Ca2+激活的K+通道阻滞剂)或10 - 5摩尔/升ODQ加10 - 7摩尔/升iberiotoxin的情况下,在苯肾上腺素引起血管收缩后,通过添加累积浓度的YC-1(10 - 10至3×10 - 7摩尔/升)和DEA/NO(10 - 8至3×10 - 5摩尔/升)在体外测试内皮依赖性血管舒张功能。我们还评估了YC-1和DEA/NO对从人桡动脉获取的血管环中cGMP水平的影响(每种药物n = 6)。YC-1(10 - 10至3×10 - 7摩尔/升)和DEA/NO(10 - 8至3×10 - 5摩尔/升)使预先用苯肾上腺素(10 - 5摩尔/升)预收缩的RA环产生浓度依赖性血管舒张(每种药物n = 20)。用ODQ、iberiotoxin或ODQ加iberiotoxin对RA环进行预孵育可显著抑制YC-1的血管舒张作用,但ODQ加iberiotoxin的抑制作用明显大于单独使用ODQ和iberiotoxin(p < 0.05)。在存在ODQ、iberiotoxin加ODQ的情况下,DEA/NO的血管舒张作用几乎完全消失,但在单独存在iberiotoxin的情况下无显著变化(p > 0.05)。DEA/NO的pEC50值显著低于YC-1的pEC50值(p < 0.01),RA环中的Emax值无变化。此外,YC-1刺激的RA环比DEA/NO刺激的RA环显示出更高的cGMP升高(p < 0.05)。这些发现表明,在人桡动脉中,YC-1比DEA/NO是更有效的舒张剂。YC-1的舒张作用可能归因于对sGC和Ca2+敏感的K+通道的刺激,而DEA/NO的舒张作用可能完全归因于对sGC的刺激。YC-1和DEA/NO可能作为血管扩张剂对冠状动脉旁路移植围手术期痉挛进行短期治疗有效。